Department of Endocrinology & Diabetes, Princess Alexandra Hospital, Brisbane, Australia.
School of Medicine, University of Queensland, Brisbane, Australia.
Diabetes Obes Metab. 2018 Apr;20(4):840-848. doi: 10.1111/dom.13157. Epub 2017 Dec 6.
To investigate the effect of glucocorticoids on brown adipose tissue (BAT) function in humans.
In a randomized double-blind cross-over design, 13 healthy adults underwent 1 week of oral prednisolone treatment (15 mg/d) and placebo with an intervening 2-week wash-out period. BAT function was assessed in response to cooling (19°C) and to a standardized meal, by measuring fluoro-deoxyglucose (FDG) uptake using positron emission tomography-computed tomography and skin temperatures overlying the supraclavicular (SCL) BAT depots using infrared thermography. Postprandial energy and substrate metabolism was assessed by indirect calorimetry.
During cooling, prednisolone significantly reduced BAT FDG uptake (standardized uptake value, SUV 6.1 ± 2.2 vs 3.7 ± 1.2; P < .05) and SCL temperature (-0.45 ± 0.1 vs -1.0 ± 0.1°C; P < .01) compared to placebo. Postprandially, prednisolone significantly blunted the rise in SCL temperature (+0.2 ± 0.1 vs -0.3 ± 0.1°C; P < .05), enhanced energy production (+221 ± 17 vs +283 ± 27 kcal/d; P < .01) and lipid synthesis (+16.3 ± 3.2 vs +23.6 ± 4.9 mg/min; P < .05). The prednisolone-induced reduction in SCL temperature significantly correlated with the reduction in FDG uptake (r = 0.65, P < .05), while the increase in energy production significantly correlated with the increase in lipogenesis (r = 0.6, P < .05).
Prolonged exposure to glucocorticoid suppresses the function of human BAT. The enhancement of energy production and lipogenesis in the face of reduced dissipation of energy as heat suggests that glucocorticoids channel energy towards fat storage after nutrient intake. This is a novel mechanism of glucocorticoid-induced obesity.
研究糖皮质激素对人体棕色脂肪组织(BAT)功能的影响。
采用随机、双盲、交叉设计,13 名健康成年人接受了为期 1 周的口服泼尼松龙治疗(15mg/d)和安慰剂治疗,中间有 2 周的洗脱期。通过正电子发射断层扫描-计算机断层扫描测量氟代脱氧葡萄糖(FDG)摄取,并使用红外热成像测量锁骨上(SCL)BAT 沉积区的皮肤温度,评估 BAT 功能对冷却(19°C)和标准餐的反应。通过间接热量法评估餐后能量和底物代谢。
在冷却期间,与安慰剂相比,泼尼松龙显著降低了 BAT FDG 摄取(标准化摄取值,SUV 6.1±2.2 与 3.7±1.2;P<.05)和 SCL 温度(-0.45±0.1 与-1.0±0.1°C;P<.01)。餐后,泼尼松龙显著抑制了 SCL 温度的升高(+0.2±0.1 与-0.3±0.1°C;P<.05),增强了能量产生(+221±17 与+283±27 千卡/天;P<.01)和脂质合成(+16.3±3.2 与+23.6±4.9 毫克/分钟;P<.05)。SCL 温度降低与 FDG 摄取减少显著相关(r=0.65,P<.05),而能量产生增加与脂肪生成增加显著相关(r=0.6,P<.05)。
长期接触糖皮质激素会抑制人体 BAT 的功能。在能量消耗减少的情况下,能量产生和脂肪生成增加表明,糖皮质激素在摄入营养后将能量引导至脂肪储存。这是糖皮质激素诱导肥胖的一种新机制。